ERBB2 and neoplasm: The American Society of Clinical Oncology (ASCO) Guideline [11], updated in 2022, now presents existing therapy regimens to address this issue [11], which was updated in 2022 (Figure 2).The mechanisms of drug resistance are complicated, such as lower binding between agents with HER2 [12], ErbB2 mutation [13,14], epigenetic changes [15], alteration of the tumor microenvironment [16], tumor stem cell self-renewal [17], and the overactivation of the signaling pathways [18].